Metagenomi Therapeutics, Inc. Operating Expenses
Metagenomi Therapeutics, Inc. (MGX) reported Operating Expenses of $28.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $28.52M, a 3.34% decline year-over-year.
- Metagenomi Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $25.84M, a 19.13% decline year-over-year.
- Metagenomi Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $28.28M, a 6.48% decline year-over-year.
- Metagenomi Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $31.50M, a 7.08% decline year-over-year.
- Metagenomi Therapeutics, Inc. operating expenses for fiscal 2025 was $121.22M, a 14.15% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. operating expenses for fiscal 2024 was $141.20M, a 14.56% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. operating expenses for fiscal 2023 was $123.25M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.52M 10-Q · filed 2026-08-10 | $54.35M 10-Q · filed 2026-08-10 | $82.63M derived: sum of 3 quarters · filed 2026-08-10 | $114.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $25.84M 10-Q · filed 2026-05-11 | $54.11M derived: sum of 2 quarters · filed 2026-05-11 | $85.61M derived: sum of 3 quarters · filed 2026-05-11 | $115.11M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $28.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $59.78M derived: sum of 2 quarters · filed 2026-03-05 | $89.28M derived: sum of 3 quarters · filed 2026-08-10 | $121.22M 10-K · filed 2026-03-05 |
| 2025-09-30 | $31.50M 10-Q · filed 2025-11-12 | $61.00M derived: sum of 2 quarters · filed 2026-08-10 | $92.94M 10-Q · filed 2025-11-12 | $123.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $29.50M 10-Q · filed 2026-08-10 | $61.45M 10-Q · filed 2026-08-10 | $91.68M derived: sum of 3 quarters · filed 2026-08-10 | $125.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $31.95M 10-Q · filed 2026-05-11 | $62.18M derived: sum of 2 quarters · filed 2026-05-11 | $96.08M derived: sum of 3 quarters · filed 2026-05-11 | $132.95M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $30.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $64.13M derived: sum of 2 quarters · filed 2026-03-05 | $101.00M derived: sum of 3 quarters · filed 2026-03-05 | $141.20M 10-K · filed 2026-03-05 |
| 2024-09-30 | $33.90M 10-Q · filed 2025-11-12 | $70.77M derived: sum of 2 quarters · filed 2025-11-12 | $110.96M 10-Q · filed 2025-11-12 | $143.55M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $36.87M 10-Q · filed 2025-08-12 | $77.06M 10-Q · filed 2025-08-12 | $109.66M derived: sum of 3 quarters · filed 2025-08-12 | $144.41M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $40.19M 10-Q · filed 2025-05-13 | $72.79M derived: sum of 2 quarters · filed 2025-05-13 | $107.54M derived: sum of 3 quarters · filed 2025-05-13 | $136.84M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $32.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $67.35M derived: sum of 2 quarters · filed 2025-03-17 | $96.65M derived: sum of 3 quarters · filed 2025-03-17 | $123.25M 10-K · filed 2025-03-17 |
| 2023-09-30 | $34.76M 10-Q · filed 2024-11-13 | $64.06M derived: sum of 2 quarters · filed 2024-11-13 | $90.65M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $29.30M 10-Q · filed 2024-08-14 | $55.90M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $26.59M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |